Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shares have increased by 9.5% in the last four weeks, closing at $29.43, with a potential upside of 75% based on Wall Street analysts' mean price target of $51.5 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $13.2, indicating variability among analysts [2] - The lowest estimate suggests a 15.5% increase from the current price, while the highest estimate indicates a potential upside of 171.8% [2] Analyst Sentiment - Analysts show a consensus that RAPP will report better earnings than previously estimated, which supports the expectation of a stock price increase [4][11] - The Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Implications - While the consensus price target may not be a reliable indicator of the extent of RAPP's potential gains, it does provide a useful guide for the direction of price movement [14]
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?